Alulis, Sarah
Bernardini, Nicoletta
Burlando, Martina
Costanzo, Antonio
Francesa Morel, Pier Cesare http://orcid.org/0000-0002-9503-016X
Gisondi, Paolo
Loconsole, Francesco
Megna, Matteo
Pellacani, Giovanni
Piaserico, Stefano
Prignano, Francesca
Secchi, Ottavio
Skroza, Nevena
Hassan, Fareen
Funding for this research was provided by:
Janssen-Cilag Ltd
Article History
Received: 29 February 2024
Accepted: 15 April 2024
First Online: 10 May 2024
Declarations
:
: Sarah Alulis, Fareen Hassan, Pier Cesare Francesa Morel, and Ottavio Secchi are employees of Janssen-Cilag. Sarah Alulis and Fareen Hassan are also shareholders of Janssen-Cilag. Nicoletta Bernardini served as an advisory board member and consultant for AbbVie, Almirall, Boehringer Ingelheim, LEO Pharma, Lilly, Janssen, Novartis, and UCB. Martina Burlando acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, LEO Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. Paolo Gisondi is an editorial board member of<i> Dermatology and Therapy</i>. Paolo Gisondi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Paolo Gisondi served as a speaker for Amgen, Almirall, AbbVie, Eli Lilly, Novartis, UCB, Sanofi, LEO pharma, and Jannsen. Francesco Loconsole has no conflict of interest outside the submitted work. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, LEO Pharma, Novartis, UCB, Janssen, and Almirall. Giovanni Pellacani acted as scientific consultant/speaker/clinical study investigator for AbbVie, Jansenn, LEO Pharma, Lilly, Novartis, Pfizer, and UCB. Stefano Piaserico acted as a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene, Galderm, Janssen, LEO Pharma, Lilly, MSD, Novartis, and Pfizer. Francesca Prignano served as an advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, LEO Pharma, Lilly, Janssen, Novartis, Biogen, Sanofi Genzyme, UCB, and Boehringer Ingelheim. Nevena Skroza has participated in clinical trials, as a member of the advisory board, and as a consultant on behalf of AbbVie, Boehringer Ingelheim, Galderma, Janssen, LEO Pharma, L'Oréal, Novartis, and Sanofi.
: This study did not involve any human subject and no ethical approval was needed due to the secondary nature of data analysis.